FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple...

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Multiple sclerosis (MS) is a leading cause of disability in young adults, with current treatments only partially addressing neurodegeneration.
• Effective therapies for progressive MS, particularly those promoting remyelination and neuronal repair, are critically needed.
• New therapeutic strategies are required to delay demyelination and associated disability in MS.

Purpose of the Study:

• To review the latest literature on therapeutic targets for progressive multiple sclerosis.
• To investigate the role of fibroblast growth factor (FGF) signaling in MS onset and progression.
• To explore potential therapeutic advances targeting the FGF/FGFR pathway for MS management.

Main Methods:

• Literature review of recent findings on FGF/FGFR signaling in multiple sclerosis.
• Analysis of FGF signaling's role in oligodendrocyte lineage, neural stem cell function, and neuroinflammation.
• Examination of studies involving FGF/FGFR-targeted interventions in MS animal models.

Main Results:

• FGF signaling is crucial for oligodendrocyte development, neural stem cell proliferation, and central nervous system myelination.
• FGF signaling plays a role in regulating neuroinflammation.
• Interventions targeting FGF and its receptor (FGFR) have shown moderate success in ameliorating MS symptoms in animal models.

Conclusions:

• The FGF/FGFR signaling pathway represents a promising therapeutic target for progressive multiple sclerosis.
• Understanding FGF/FGFR signaling offers fresh insights into managing MS and developing new treatments.
• Targeting FGF/FGFR may offer a novel approach to promote remyelination and neuronal repair in MS.